FDG PET/MR Imaging of Peripheral Pain Generators

Recruitment & Eligibility

Status: Not yet recruiting

Sex: All

Target Recruitment: 128

Inclusion Criteria

Inclusion Criteria: Persistent Post-Surgical Pain Patients - 18-85 years old - Presents with persistent pain with pain score of =4 on Numerical Rating Scale [0:10] for at least 6 months following joint arthroplasty or arthroscopy. - Able and willing to provide informed consent - Willing and able to undergo PET/MRI (arthroplasty and arthroscopy participants) and PET/CT (arthroplasty participants only) Inclusion Criteria: Asymptomatic controls - 18-85 years old - Asymptomatic (pain score of =2 on the NRS) for at least 6 months following joint arthroplasty or arthroscopy. - Able and willing to provide informed consent - Willing and able to undergo PET/MRI Exclusion Criteria: - Inability to understand and communicate with the investigators to complete the study-related questionnaires. - Any co-morbidity which results in severe systemic disease limiting function as defined by the American Society of Anesthesiology (ASA) physical status classification > 3, such as the presence of current or past (6 months) pulmonary, hepatic, renal disease, arthritis, hematopoietic, and neurological diseases not related to chronic pain. - Pregnant or breastfeeding. (Individuals with childbearing potential will be asked to verbally confirm they are not pregnant. If they cannot confirm, they will have a urine pregnancy test either at the imaging study visit or within 7 days prior to the imaging study visit.) - Subject with contraindication(s) to or inability to undergo PET/MRI - Current diagnosis of malignancy of any kind. Participants in remission for at least two years and not undergoing any treatment may be considered per investigator discretion - Current enrollment in a scientific interventional or treatment study. - Subject unable or unwilling to provide informed consent

Exclusion Criteria

Not provided

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in SUVmax (chronic pain);SUVmax (chronic pain vs healthy);Location of Pain Compared to Target-to-Background (TTB) or SUVmax

Secondary Outcome Measures

Name	Time	Method
Number of Participants Where Standard FDG dose was sufficient to detect region of pain (symptomatic groups);Variation of the maximum ratio of SUV (SUVRmax) in asymptomatic controls vs symptomatic;Variation of the maximum ratio of SUV (SUVRmax) in symptomatic participants;Radiology Review Scores;Change in Pain Scores (chronic pain)